Souhaitez-vous accéder aux communiqués récents ?

Eko Vet+TM | CANINEBEAT® AI helps veterinarians detect, visualize, and grade heart murmurs in dogs that can otherwise go undetectedThe CANINEBEAT® AI algorithm detects heart murmurs associated with...

In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight...

Boehringer is expanding its global Computational Innovation footprint with a new center dedicated to AI and machine learning (ML) in the UKEstablishing a presence in King’s Cross, London, places...

This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn. Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results...

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).  ...

LENZELTA® is a new vaccine significantly reducing the incidence and severity of clinical mastitis in vaccinated cows and heifers1. Administration is simple with two doses during the dry-off...

Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer.

•    Ecuador aims to become one of the first rabies free countries in Latin America.•    Joint efforts with the Ministry of Public Health focus on vaccination, education and epidemiological...

Intended audience: global business, financial and trade media HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025Group net sales increased 7.3%* to EUR 27.8 billion in...

43% of pet owners report that their pets experienced parasite infections, with 75% looking for clearer parasite prevention advice.Veterinarians are seen as the most trusted source of pet health...